Taj Pharmaceuticals as Manufacturer of Nystatin Oral Tablets 500,000 I.U Tablets Nystatin Oral Tablets 500,000 I.U Tablets manufacturer in India {Taj Pharmaceuticals}; best quality supplier and exporter of Nystatin Oral Tablets 500,000 I.U Tablets Taj Pharmaceuticals manufactures a wide range of pharmaceuticals formulation involving Tablets / Tablets / Injections and Orals. Taj Pharma India team has an excellent expertise in manufacturing and export of Nystatin Oral Tablets 500,000 I.U Tablets. Taj Pharmaceuticals places its main business as a Pharmaceuticals manufacturing and exports of generic drug supply of Nystatin Oral Tablets 500,000 I.U Tablets; primarily of pharmaceuticals preparations known as Nystatin Oral Tablets 500,000 I.U Tablets; as well as more than 100+ generic equivalent drug. Taj Pharmaceuticals has performed these business activities related to exports of Nystatin Oral Tablets 500,000 I.U Tablets for major foreign-affiliated pharmaceutical import companies, ministry of health, tenders etc. and have enjoyed the full confidence of these companies, instructions and governments. Taj Pharma Group Under close cooperation between the formulation manufacturing division, active ingredient division and the technology development division for major generic formulations such as Nystatin Oral Tablets 500,000 I.U Tablets; at Taj Pharma we will appropriately meet diverse needs for Nystatin Oral Tablets 500,000 I.U Tablets export manufacturing in a wide range of activities from investigation of possible formulations of Nystatin Oral Tablets 500,000 I.U Tablets, formulation development, making applications to the international regulatory authorities for marketing approval, validation of Nystatin Oral Tablets 500,000 I.U Tablets through to manufacturing scale production at our cGMP compliant manufacturing units of Taj Pharmaceuticals under the umbrella of Taj Pharma Group. We at Taj Pharma intend to make our manufacturing systems comply with the requirements of the FDA (cGMP) such that pilot plant scale production of products in the stage of clinical development or for use in clinical studies, as well as manufacture of products in small lots are practicable to ensure a highly stable pharmaceuticals formulations of generic equivalent and bio-similar products. We conduct extensive bio-similar and bio-equivalency studies for all our formations